RASP.US Rasna Therapeutics Inc
- Market cap
- USD 386K
- P/E
- -
- P/B
- 0.31x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Mar 2024.
Is RASP.US undervalued?
Graham numberThe Graham number of Rasna Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rasna Therapeutics Inc fundamental analysis
No fundamental analysis for Rasna Therapeutics Inc yet.
Rasna Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rasna Therapeutics Inc
Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, develops therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma in the United States. It is developing RASP-201, an orally dosed selective reversible inhibitor of lysine specific demethylase (LSD1), which is a pathway that blocks differentiation and confers a poor prognosis to AML; and RASP-301. The company was formerly known as Rasna Therapeutics, Inc. and…
Full company profileRasna Therapeutics Inc financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 2 quarters up to Mar 31, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rasna Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | -350.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -350.00 | 0.00 | 0.00 | -3.46K | -4.83K | -3.47K | -1.64K | -314.00 | 0.00 | 0.00 | - |
| Operating Income | -40.0K | -16.8K | -62.2K | -4.54M | -4.07M | -915K | -5.43M | -248K | 141K | -4.24M | -393K |
| EBITDA | -40.0K | -16.8K | -62.2K | -4.54M | -4.07M | -913K | -555K | -248K | 255K | -4.05M | 2.36K |
| Net Income | -40.0K | -16.8K | -62.2K | -4.43M | -4.08M | -936K | -5.35M | -876K | -687K | -4.44M | -487K |
| EPS | 0.00 | 0.00 | -0.01 | -0.07 | -0.06 | -0.01 | -0.08 | -0.01 | -0.01 | -0.01 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 6.69K | 385.00 | 259.00 | 9.08M | 5.23M | 4.95M | 32.9K | 44.6K | 85.3K | 95.7K | 48.6K |
| Total Liabilities | 980.00 | 11.4K | 72.6K | 1.53M | 2.12M | 2.41M | 2.71M | 2.71M | 1.77M | 2.05M | 2.23M |
| Shareholders' Equity | 5.71K | -11.1K | -72.3K | 7.55M | 3.11M | 2.54M | -2.67M | -2.66M | -1.69M | -1.96M | -2.18M |
| Cash & Short-term Investments | 6.34K | 35.00 | 134.00 | 4.05M | 42.7K | 50.1K | 14.2K | 10.8K | 39.4K | 75.0K | 1.39K |
| Total Debt | - | 10.0K | 8.56K | - | 137K | 265K | 522K | 592K | 220K | 211K | 304K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -40.0K | -12.9K | -11.5K | -2.96M | -2.63M | -92.6K | -251K | -293K | -313K | -8.52K | -166K |
| Capital Expenditure | 10.5K | 10.5K | 10.5K | 10.5K | 4.07K | 0.00 | 0.00 | 3.00 | 3.00 | 4.00 | 8.00 |
| Free Cash Flow | -40.0K | -12.9K | -11.5K | -2.97M | -2.63M | -92.6K | -251K | -293K | -313K | -8.52K | -166K |
| Ratios | |||||||||||
| ROE | -701.8% | - | - | -58.7% | -131.3% | -36.9% | - | - | - | - | - |
| ROA | -598.9% | -4,352.5% | -24,025.9% | -48.8% | -78.0% | -18.9% | -16,230.6% | -1,965.1% | -805.6% | -4,644.7% | -1,001.8% |
| Debt to Equity | - | - | - | - | 0.04x | 0.10x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rasna Therapeutics Inc dividends
Rasna Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 3.25:1 on Sep 20, 2016.
Who owns Rasna Therapeutics Inc
- Insiders 85.19%
- Institutions 0.00%
- Public & others 14.81%
- Shares outstanding 772M
- Free float 114M
Rasna Therapeutics Inc company profile
- Company name
- Rasna Therapeutics Inc
- Ticker
- RASP.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- September
- Address
- 5 Penn Plaza, New York, NY, United States, 10001
- Phone
- 646 396 4087
- Website
- rasna.com
About Rasna Therapeutics Inc
Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, develops therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma in the United States. It is developing RASP-201, an orally dosed selective reversible inhibitor of lysine specific demethylase (LSD1), which is a pathway that blocks differentiation and confers a poor prognosis to AML; and RASP-301. The company was formerly known as Rasna Therapeutics, Inc. and changed its name to Actavia Life Sciences, Inc. in October 2023. Actavia Life Sciences, Inc. was founded in 2013 and is based in New York, New York.
Rasna Therapeutics Inc management
2- Ms. Keeren ShahChief Financial Officer · born 1976
- Mr. Willy Jules SimonExecutive Chairman · born 1951